Zobrazeno 1 - 1
of 1
pro vyhledávání: ''
Publikováno v:
Annals of Hematology
The B cell surface antigen CD19 is a target for treating B cell malignancies, such as B cell precursor acute lymphoblastic leukemia and B cell non-Hodgkin lymphoma. The BiTE® immuno-oncology platform includes blinatumomab, which is approved for rela